BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
-11.11%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.07B
AUM Growth
-$1.54B
(-18%)
Cap. Flow
-$234M
Cap. Flow
% of AUM
-3.31%
Top 10 Holdings %
Top 10 Hldgs %
34.72%
Holding
187
New
10
Increased
57
Reduced
82
Closed
15
Top Buys
| 1 |
Intuitive Surgical
ISRG
|
$58.1M |
| 2 |
Pfizer
PFE
|
$41.4M |
| 3 |
Harmony Biosciences
HRMY
|
$28.1M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$25.4M |
| 5 |
Celldex Therapeutics
CLDX
|
$24.9M |
Top Sells
| 1 |
Elevance Health
ELV
|
$98M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$85.7M |
| 3 |
AbbVie
ABBV
|
$47.7M |
| 4 |
Bristol-Myers Squibb
BMY
|
$46.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$42.9M |
Sector Composition
| 1 | Healthcare | 98.26% |
| 2 | Industrials | 0.38% |
| 3 | Energy | 0.03% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Arcus Biosciences
RCUS
$1.3B
| $2.28M | 0.03% |
90,100
-21,600
| -19% | -$547K |
|
127
Sanofi
SNY
$113B
| $2.12M | 0.03% |
42,300
-1,300
| -3% | -$65K |
|
128
Kosmos Energy
KOS
$784M
| $1.97M | 0.03% |
318,300
-93,700
| -23% | -$580K |
|
|
129
Bristol-Myers Squibb
BMY
$96B
| $1.92M | 0.03% |
24,907
-603,221
| -96% | -$46.5M |
|
|
CELL
130
DELISTED
PhenomeX Inc. Common Stock
CELL
| $1.91M | 0.03% |
385,014
| – | – |
|
131
Ultragenyx Pharmaceutical
RARE
$3.07B
| $1.85M | 0.03% |
31,000
+5,300
| +21% | +$316K |
|
132
Cencora
COR
$56.7B
| $1.84M | 0.03% |
13,000
| – | – |
|
133
NovoCure
NVCR
$1.37B
| $1.76M | 0.02% |
25,300
+16,800
| +198% | +$1.17M |
|
|
BCYC
134
Bicycle Therapeutics
BCYC
$496M
| $1.42M | 0.02% |
84,400
+47,900
| +131% | +$804K |
|
135
Seer Inc
SEER
$118M
| $1.22M | 0.02% |
136,133
| – | – |
|
136
Kura Oncology
KURA
$713M
| $1.17M | 0.02% |
63,700
-2,280
| -3% | -$41.8K |
|
137
Labcorp
LH
$23.2B
| $996K | 0.01% |
4,947
| – | – |
|
138
Krystal Biotech
KRYS
$4.35B
| $880K | 0.01% |
13,400
-400
| -3% | -$26.3K |
|
|
INBX
139
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $869K | 0.01% |
76,600
+26,900
| +54% | +$305K |
|
140
McKesson
MCK
$85.5B
| $828K | 0.01% |
2,537
+263
| +12% | +$85.8K |
|
141
Intellia Therapeutics
NTLA
$1.29B
| $817K | 0.01% |
15,794
-500
| -3% | -$25.9K |
|
142
Xencor
XNCR
$610M
| $725K | 0.01% |
26,500
-15,100
| -36% | -$413K |
|
143
Dr. Reddy's Laboratories
RDY
$11.9B
| $687K | 0.01% |
62,000
+19,500
| +46% | +$216K |
|
144
Relmada Therapeutics
RLMD
$54.8M
| $665K | 0.01% |
35,000
+19,000
| +119% | +$361K |
|
145
Alphabet (Google) Class C
GOOG
$2.84T
| $656K | 0.01% |
6,000
+3,300
| +122% | +$361K |
|
146
Arcturus Therapeutics
ARCT
$485M
| $623K | 0.01% |
39,550
-1,350
| -3% | -$21.3K |
|
147
Viridian Therapeutics
VRDN
$1.53B
| $567K | 0.01% |
+49,000
| New | +$567K |
|
148
Caribou Biosciences
CRBU
$174M
| $382K | 0.01% |
+70,300
| New | +$382K |
|
149
VanEck Gold Miners ETF
GDX
$19.9B
| $367K | 0.01% |
13,400
| – | – |
|
|
SLN
150
Silence Therapeutics
SLN
$269M
| $361K | 0.01% |
30,483
-16,183
| -35% | -$192K |
|